Allergan Bolsters its CNS Pipeline with Heptares’ GPCR Targeted Therapies
By Taskin Ahmed & Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 4 (Table of Contents)
Published: 27 Apr-2016
DOI: 10.3833/pdr.v2016.i4.2156 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Leaving behind its much anticipated collaboration with Pfizer, Allergan inked an R&D and commercialisation agreement to acquire global rights to Heptares Therapeutics’ novel G protein-coupled receptor (GPCR) targeted therapies for Alzheimer’s disease and other cognitive and psychotic disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS